1. Non-GIST Soft Tissue Sarcoma: Biology and Basics of Targeted Therapy

2. Sarcoma

3. Simplest Conceptual Level

4. Mutational Heterogeneity and the Search for New Cancer-Associated Genes

6. Mutational Heterogeneity and the Search for New Cancer-Associated Genes

7. Considerations When Selecting Therapy for Sarcoma

8. Chemotherapy Plus Ifosfamide in STS

9. Advanced Disease

10. What Guides Our Practice?

11. Doxorubicin-Based Chemotherapy for Soft Tissue Sarcoma

12. Major Non-GIST Sarcoma Studies Reported Since 2011

13. Doxorubicin vs Intensified Doxorubicin Plus Ifosfamide for Advanced STS: Phase 3

14. Doxorubicin vs Intensified Doxorubicin Plus Ifosfamide: Post-Protocol Treatment

15. First-Line Gemcitabine + Docetaxel vs Doxorubicin in Unresectable/Metastatic STS: GeDDiS

16. GeDDiS: PFS Results

17. GeDDiS: OS Results

18. GeDDiS: Subgroup Analyses

19. Pazopanib for Treatment of Metastatic STS: Phase 3 PALETTE Study

20. PDGFR

21. PDGFRα Is an Active Mediator of Rapamycin-Induced Akt Activation

22. Olaratumab in Advanced STS: Phase 1b/2 Study

23. Statistical Assumptions (Phase 2)

24. Overall Tumor Response (ITT; Phase 2)

25. PFS and OS in the ITT Population (Phase 2)

26. Liposarcoma

27. Well Differentiated/Dedifferentiated Liposarcoma

28. Delayed Response to Treatment

29. Palbociclib in Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma: Phase 2

30. PVNS: TGCT

31. PVNS and GCT-TS: High Morbidity

32. PVNS/TGCT

33. Imatinib Mesylate for the Treatment of Locally Advanced and/or Metastatic TGCT/PVNS

34. Conclusions

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)